• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

    8.550 +0.080 (+0.94%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Amicus Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
    One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
    Via Investor's Business Daily
    Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
    The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
    Via Benzinga
    Amicus Therapeutics: Q1 Earnings Insights
     
    Via Benzinga
    Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    The Latest Analyst Ratings for Amicus Therapeutics
     
    Via Benzinga
    Earnings Scheduled For March 1, 2023
    Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
    Via Benzinga
    Earnings Preview: Amicus Therapeutics
     
    Via Benzinga
    FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
     
    Via Benzinga
    Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. 
    Via Benzinga
    Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Recap: Amicus Therapeutics Q3 Earnings
    Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
    October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
    Via Benzinga
    U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Participation at World Muscle Society 2022
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.